Time: 2024-09-13
research_worker caution against order medicine for conditions they are not license for , as it could worsen the situation despite good purpose . A survey show at the ERS Congress in Vienna and print in The Lancet Respiratory Medicine highlight the pressing need for effective treatment for severe shortness of breath , a symptom without approve drug in the UK and many other state . chronic respiratory disease causing severe shortness_of_breath not only affect patient ' quality of life but also airs significant clinical and economic burden on healthcare systems.
Prior to the test , doctor specialize in respiratory and palliative care were survey , disclosure a park tendency of off - label order - exploitation medicine in a manner different from their intend use . Among these prescription were benzodiazepine and selective-serotonin_reuptake_inhibitor , include the antidepressant mirtazapine . While early survey propose mirtazapine 's potential in pull_off shortness_of_breath , a large - scale International test found no significant improvement compare to a placebo . patient pickings mirtazapine experience More side effects and necessitate increase hospital and family care.
The global prevalence of chronic respiratory disease , affect 454.6 million person , is expect to rise with an ripening population . COPD and ILD , affect over 217 million people worldwide , are park perpetrator of severe shortness_of_breath . Off - label use can be safe under proper guidance , especially when license medicine fail to control symptom in serious conditions . The importance of thoroughly measure medicine in palliative care , include those for shortness_of_breath , is stress to avoid potential harm.
Professor Irene Higginson of Kings College London stress the straiten impact of severe shortness_of_breath on patient and their love one , lead to increase healthcare use . With effective treatment scarce , off - label order , though park , may not always be beneficial . The survey 's decision that mirtazapine is not advisable for shortness_of_breath treatment underscore the importance of careful consideration when exploitation unaccredited medicine . research into option therapy for severe shortness_of_breath is crucial , with the recommendation for clinician to prioritize early designation and not - pharmacological intervention until More evidence - establish treatment are available.
In decision , the survey 's findings call for timid order practice and the need for rigorous test in palliative care to guarantee patient safety and effective symptom management . clinician are urge to research not - pharmacological approach and support services to relieve shortness_of_breath until more definitive treatment option are establish . The research paper is print in The Lancet Respiratory Medicine on September 9 , 2024 , offer foster penetration into pull_off shortness_of_breath and the BETTER - B program.
Business
